Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App Go offline with the Player FM app!
How do you know when it’s time to make your next big career move? With International Women’s Day around the corner, we are excited to feature Avni Patel Thompson, Founder and CEO of Milo. Avni is building technology that directly supports the often overlooked emotional and logistical labor that falls on parents—especially women. Milo is an AI assistant designed to help families manage that invisible load more efficiently. In this episode, Avni shares her journey from studying chemistry to holding leadership roles at global brands like Adidas and Starbucks, to launching her own ventures. She discusses how she approaches career transitions, the importance of unpleasant experiences, and why she’s focused on making everyday life easier for parents. [01:26] Avni's University Days and Early Career [04:36] Non-Linear Career Paths [05:16] Pursuing Steep Learning Curves [11:51] Entrepreneurship and Safety Nets [15:22] Lived Experiences and Milo [19:55] Avni’s In Her Ellement Moment [20:03] Reflections Links: Avni Patel Thompson on LinkedIn Suchi Srinivasan on LinkedIn Kamila Rakhimova on LinkedIn Ipsos report on the future of parenting About In Her Ellement: In Her Ellement highlights the women and allies leading the charge in digital, business, and technology innovation. Through engaging conversations, the podcast explores their journeys—celebrating successes and acknowledging the balance between work and family. Most importantly, it asks: when was the moment you realized you hadn’t just arrived—you were truly in your element? About The Hosts: Suchi Srinivasan is an expert in AI and digital transformation. Originally from India, her career includes roles at trailblazing organizations like Bell Labs and Microsoft. In 2011, she co-founded the Cleanweb Hackathon, a global initiative driving IT-powered climate solutions with over 10,000 members across 25+ countries. She also advises Women in Cloud, aiming to create $1B in economic opportunities for women entrepreneurs by 2030. Kamila Rakhimova is a fintech leader whose journey took her from Tajikistan to the U.S., where she built a career on her own terms. Leveraging her English proficiency and international relations expertise, she discovered the power of microfinance and moved to the U.S., eventually leading Amazon's Alexa Fund to support underrepresented founders. Subscribe to In Her Ellement on your podcast app of choice to hear meaningful conversations with women in digital, business, and technology.…
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
While annual major scientific meetings are the venue to stay up-to-date in your clinical area, it is near impossible to attend all breaking news sessions. Through interviews with experts, Healio’s Meeting Mic provides a post-meeting wrap-up of the most important content that listeners can consume on-the-go.
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
While annual major scientific meetings are the venue to stay up-to-date in your clinical area, it is near impossible to attend all breaking news sessions. Through interviews with experts, Healio’s Meeting Mic provides a post-meeting wrap-up of the most important content that listeners can consume on-the-go.
In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition with a focus on leukemia, as well as Healio’s top headlines from the meeting. Aaron T. Gerds, MD, MS, discusses how socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia. :24 Hua Zhang, MD, PhD, reviews findings of bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia. 6:29 Moath Albliwi, MD, discusses the results of a study he co-presented examining treatment of elderly patients with acute myeloid leukemia. 00:00 Alexey Danilov, MD, PhD, reviews the efficacy of epcoritamab among heavily pretreated patients with advanced chronic lymphocytic leukemia. 00:00 Lee Greenberger, PhD, discusses results of the AMPLIFY study. 16:30 Read the full coverage here: Socioeconomic factors a barrier to HSCT for people with acute myeloid leukemia Bicistronic CAR-T effective for children with relapsed B-ALL VIDEO: Study probes treatment of elderly patients with acute myeloid leukemia First-line regimen improves PFS in chronic lymphocytic leukemia Epcoritamab exhibits ‘very encouraging’ efficacy in heavily pretreated CLL Addition of blinatumomab to chemotherapy improves outcomes for children with B-cell ALL Disclosures: Albliwi reports no relevant financial disclosures. Danilov reports research funding from and/or consulting roles with AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech, Genmab, Incyte, Janssen and other companies. Please see the abstract for all other researchers’ relevant financial disclosures. Gerds reports consulting roles with AbbVie, Bristol Myers Squibb, Disc Medicine, GSK, PharmaEssentia and Rain Oncology. Please see the abstract for all other researchers’ relevant financial disclosures. Greenberger reports no relevant financial disclosures. Rau reports consulting/advisory roles with and/or honoraria from Jazz Pharmaceuticals and Servier. She also reports her spouse is employed by AbbVie. Please see the abstract for all other researchers’ relevant financial disclosures. Zhang reports no relevant financial disclosures.…
In this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2024, as well as Healio’s top headlines from the meeting. Judy Garber, MD, MPH, chief of the division of cancer genetics and prevention at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, reviews results of the OlympiA trial. :25 Raza Hoda, MD, a pathologist at Cleveland Clinic and assistant professor of pathology at Cleveland Clinic Lerner College of Medicine, discusses results from the DESTINY-Breast04 and DESTINY-Breast06 trials. 1:55 Shimoli Barot, MD, medical oncologist at Cleveland Clinic Cancer Institute, examines the results of a study observing exceptional treatment response in patients with metastatic breast cancer. 6:02 Eleonora Teplinsky further discusses results of the COMET trial. 10:38 Jennifer A. Ligibel discusses an overview analysis looking at the relationship between body mass index at the time of breast cancer diagnosis and distant recurrence. 19:27 Read the full coverage here: VIDEO: OlympiA trial shows ‘continued benefit’ in breast cancer survival VIDEO: Study investigates HER2-low, ultralow eligibility for trastuzumab deruxtecan VIDEO: Study investigates exceptional treatment response in metastatic breast cancer Active monitoring safe for some patients with low-risk ductal carcinoma in situ Source: Hwang ES, et al. Abstract GS2-05. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio. Terminated study’s ‘challenges’ may guide future trials of MRD-guided breast cancer therapy Source: Turner N, et al. Abstract GS3-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio. Obesity elevates risk for distant recurrence, mortality in early-stage breast cancer Source: Pan H, et al. Abstract GS2-09. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio. Disclosures: Barot reports no relevant financial disclosures. Garber reports no relevant financial disclosures. Hoda reports no relevant financial disclosures. Teplinsky reports no relevant financial disclosures.…
In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition, as well as Healio’s top headlines from the meeting. Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients’ concerns as AI’s role in medicine invariably expands. :24 Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29 Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30 Read the full coverage here: AI in hematology: ‘The good, the bad and the ugly’ Mitigating financial toxicity ’better than any drug’ for people with cancer Etavopivat could offer ‘great benefit’ in sickle cell disease ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity Disclosures: Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.…
In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology 2024 Meeting with a focus on AMD and retina. David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration. :28 Douglas Love discusses the company’s phase 3 program in geographic atrophy. 2:37 Pravin U. Dugel, MD, discusses the next steps for the phase 3 SOL-1 and SOL-R studies. 3:54 Jeremiah Brown, MS, MD, presents results from the phase 4 Elevatum trial investigating faricimab for diabetic macular edema. 5:17 Read the full coverage here: https://www.healio.com/news/ophthalmology/20241024/video-axitinib-shows-clinically-meaningful-treatment-burden-reduction-in-wet-amd https://www.healio.com/news/ophthalmology/20241023/video-phase-3-geographic-atrophy-program-focuses-on-visual-acuity https://www.healio.com/news/ophthalmology/20241021/video-ocular-therapeutix-shares-update-on-phase-3-axpaxli-studies https://www.healio.com/news/ophthalmology/20241018/video-faricimab-shows-amazing-outcomes-in-underrepresented-patients-with-dme Teleretinal screening for diabetic retinopathy beneficial Source: Weng CY. The use of teleretinal screening for diabetic retinopathy. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago. Oral treatment aims to reduce GA progression by slowing vitamin A dimerization Source: Melamud A. Gildeuretinol in geographic atrophy: Results from SAGA, a 2-year, randomized, double-masked, placebo-controlled Study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago. Fas inhibitor shows benefit in some cases of macula-off rhegmatogenous retinal detachment Source: Borkar DS. Fas inhibition with intravitreal ONL1204 for the treatment of macula-off rhegmatogenous retinal detachment: Results from a phase 2 study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago. Disclosures: Brown reports being an investigator and speaker for Genentech and a researcher for EyeBio, Regeneron and Regenxbio. Dugel reports being executive chairman, president and CEO of Ocular Therapeutix. Eichenbaum reports being a consultant and investigator for Ocular Therapeutix. Love reports being president and CEO of Annexon Biosciences.…
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 European Society for Medical Oncology Congress with a focus on leukemia. Douglas Tremblay, MD, highlights an abstract related to leukemia at the conference. :29 Douglas Tremblay, MD, discusses another abstract related to leukemia. 5:23 Noah M. Merin, MD, PhD, focuses on recent findings in AML, ALL and MDS presented at the Congress. 9:08 Rosalie Griffin, PhD, discusses her winning poster on biomarker testing in lymphoid malignancies. 12:57 Rosalie Griffin, PhD, also shares her thoughts on a presentation looking at point mutations in lymphoid malignancies. 17:13 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20241009/video-new-car-tcell-product-may-reduce-side-effects-in-all https://www.healio.com/news/hematology-oncology/20241009/video-timdarpacept-examined-in-dedicated-chronic-myelomonocytic-leukemia-trial https://www.healio.com/news/hematology-oncology/20241009/video-no-association-between-point-mutations-and-blood-cancer-precursors https://www.healio.com/news/hematology-oncology/20241009/video-biomarkers-relationship-with-blood-cancers-examined-at-esmo Disclosures: Griffin reports no relevant financial disclosures. Tremblay reports contracted research funding paid to his institution from Cogent Biosciences, Gilead, Sobi and Sumitomo, and consulting fees from AbbVie, Cogent Biosciences, GSK, Novartis, Pharmaessentia, Sierra Oncology and Sobi. Healio could not confirm relevant financial disclosures for Merin at the time of posting.…
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting. Benjamin P. Levy, MD, discusses key takeaways from the meeting. 0:28 Read the full coverage here: Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’ Source: Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Perioperative nivolumab improves outcomes in resectable NSCLC Source: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Despite progress, barriers to lung cancer biomarker testing persist Source: Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Disclosures: Healio could not confirm relevant financial disclosures for Levy at the time of posting.…
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting. Andrew Hantel, MD, discusses results of a study on racial disparities in acute myeloid leukemia trials. :27 Christine McMahon, MD, discusses results of the phase 3 ASC4FIRST study, which examined asciminib versus tyrosine kinase inhibitors for patients with newly diagnosed chronic-phase CML. 3:30 Andrew Hantel, MD, discusses researching inequities in acute myeloid leukemia treatment in historically marginalized communities. 4:35 Christine McMahon, MD, presents results of a randomized trial of a care model for patients with acute myeloid leukemia and myelodysplastic syndrome. 7:09 Christine McMahon, MD, highlights the ACCESS study into post-transplant graft-versus-host disease, which produced “impressive” rates of post-transplant overall survival at 1 year. 10:22 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240625/video-a-patients-raceethnicity-affects-eligibility-for-acute-myeloid-leukemia-trials https://www.healio.com/news/hematology-oncology/20240620/video-strong-results-for-asciminib-in-chronic-myelogenous-leukemia https://www.healio.com/news/hematology-oncology/20240625/video-treatment-delays-do-not-lead-to-acute-myeloid-leukemia-survival-disparities https://www.healio.com/news/hematology-oncology/20240620/video-palliative-care-model-increases-quality-of-life-for-patients-with-leukemia https://www.healio.com/news/hematology-oncology/20240620/video-study-produces-impressive-posttransplant-graftversushost-disease-survival-rates Disclosures: Hantel reports no relevant financial disclosures. McMahon reports receiving institutional funding from Syndax and Syros and serving on a safety monitoring committee for Kura Oncology.…
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia, as well as Healio’s top headlines from the meeting. Jorge E. Cortes, MD, discusses how asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia. :27 Oreofe O. Odejide, MD, MPH, highlights the importance of this study. 3:30 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240531/asciminib-may-transform-treatment-paradigm-for-chronic-myeloid-leukemia New approach ‘redefining what is a suitable donor’ for stem cell transplant Source: Al Malki MM, et al. Abstract 6503. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago. Disclosures: Cortes reports research funding to his institution from or consultant/advisory roles with Gilead Sciences, Jazz Pharmaceuticals, Novartis, Pfizer, Takeda and other companies.…
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting. Joseph A. Greer, PhD, discusses how early palliative care via telehealth had an equivalent impact on quality of life as in-person visits for patients with advanced non-small cell lung cancer. :27 Charu Aggarwal, MD, MPH, FASCO, further discusses these findings during a press briefing. 3:30 Heinz-Josef Lenz, MD, shares his thoughts on the first-line immunotherapy combination of nivolumab and ipilimumab in colorectal cancer. 4:35 Fumiko Chino, MD, discusses findings on the need for a more effective and transparent prior authorization process to ensure patients receive timely access to essential pain management. 7:09 Suneel Kamath, MD, provides an overview of findings assessing how the microbiome profile of early-onset pancreatic adenocarcinoma is distinct from that of average-onset disease. 10:22 Julie R. Gralow, MD, FACP, FASCO, discusses the important implications of a prospective study on young breast cancer survivors who attempted pregnancy and became pregnant. 12:54 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240602/we-have-the-technology-telehealth-increases-access-to-palliative-care-for-cancer https://www.healio.com/news/hematology-oncology/20240602/practicechanging-data-support-firstline-immunotherapy-combination-in-colorectal-cancer https://www.healio.com/news/hematology-oncology/20240531/findings-highlight-need-to-improve-prior-authorization-process-for-cancer-pain-management https://www.healio.com/news/hematology-oncology/20240603/tumor-microbiome-profiles-in-pancreatic-cancer-differ-by-age-of-onset https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets Glucose-lowering drugs reduce risk for obesity-related cancers Source: Lin CH, et al. Abstract 10508. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago. Chemotherapy regimen improves survival in advanced esophageal cancer Source: Hoeppner J, et al. Abstract LBA1. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago. Disclosures: Chino reports no relevant financial disclosures. Greer reports a consulting role with BeiGene; research funding from Blue Note Therapeutics and NCCN/AstraZeneca; and royalties from Oxford University Press and Springer Publishing Company. Please see the abstract for all other researchers’ relevant financial disclosures. [JJ1] Kamath reports no relevant financial disclosures. Lenz reports honoraria from, consulting/advisory roles with, or travel, accommodations or expenses from 3T Biosciences, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Fulgent Genetics, G1 Therapeutics, GSK, Isofol Medical, Jazz Pharmaceuticals, Merck Serono, Oncocyte and Roche. Please see the abstract for all other researchers’ relevant financial disclosures.…
In this episode of Meeting Mic, we bring you Healio’s top headlines from ACR Convergence 2023. Eric Roberts, PhD, MPH, compares the uptake of biosimilar infliximab among patients with Medicare, Medicaid and private insurance in the U.S. :19 Shivani Garg, MD, MS, discusses how a therapeutic range of hydroxychloroquine blood levels may reduce the odds of high lupus disease activity. 2:09 Kaleb Michaud, PhD, discusses patients with rheumatoid arthritis who reported having long COVID in the past year demonstrating “many symptoms” of long COVID prior to initial infection. 12:00 Leonard H. Calabrese, DO, highlights the “year in review”, issues in vasculitis, and cautionary notes on CAR T cell therapies. 14:18 Jill Buyon, MD, discusses how pregnant patients with very low anti-Ro antibody titers of less than 1,000 units per mL have minimal-to-no risk for fetal atrioventricular block. 15:15 Read the full coverage here: https://www.healio.com/news/rheumatology/20231113/medicare-fails-to-keep-up-with-medicaid-private-market-on-infliximab-biosimilar-uptake https://www.healio.com/news/rheumatology/20231120/stay-within-hydroxychloroquine-therapeutic-threshold-to-reduce-active-lupus-flare-risk https://www.healio.com/news/rheumatology/20231116/patients-with-rheumatoid-arthritis-report-many-symptoms-of-long-covid-prior-to-infection @LCalabreseDO https://www.healio.com/news/rheumatology/20231113/pregnant-patients-with-low-antiro-titers-have-little-to-no-risk-for-fetal-heart-block Disclosures: Roberts, Garg, Michaud and Calabrese report no relevant financial disclosures. Buyon reports financial disclosures with Bristol-Myers Squibb, GlaxoSmithKline and Related Sciences.…
In this episode of Meeting Mic, we bring you Healio’s top headlines from ACG 2023. Paul Feuerstadt, MD, FACG, AGAF, discusses data that link health-related quality of life and microbiome composition among patients with recurrent Clostridioides difficile infection. :38 Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial for ulcerative colitis. 7:52 Jan Wehkamp , MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response patients with ulcerative colitis. 12:08 Paul Feuerstadt also discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics. 15:32 Thomas F. Imperiale, MD, discusses the results of the BLUE-C study, which evaluated the clinical performance of Cologuard, a next-generation, multitarget stool DNA test. 21:08 Read the full coverage here: https://www.healio.com/news/gastroenterology/20231023/video-rebyota-not-only-shuts-down-recurrence-also-affects-quality-of-life-in-c-diff https://www.healio.com/news/gastroenterology/20231025/video-risankizumab-a-great-option-for-patients-induces-clinical-remission-in-uc https://www.healio.com/news/gastroenterology/20231024/video-more-than-75-of-uc-patients-achieve-clinical-response-at-24-weeks-with-tremfya https://www.healio.com/news/gastroenterology/20231025/video-future-is-now-here-for-recurrent-c-difficile-thanks-to-live-biotherapeutics https://www.healio.com/news/gastroenterology/20231025/sensitivity-of-nextgeneration-cologuard-in-precancer-detection-numerically-exceeded-fit Disclosures: Feuerstadt reports financial relationships with Ferring Pharmaceuticals, Regeneron Pharmaceuticals, Seres Therapeutics and Takeda Pharmaceuticals. Imperiale reports grant and research support from Exact Sciences. Loftus reports financial relationships with AbbVie, Alvotech, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Exact Sciences, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Scopes, Janssen, KSL Diagnostics, Lilly, Morphic, Ono Pharma, Pfizer, Protagonist, Receptos, Robarts Clinical Trials, Scipher Medicine, Sun Pharma, Surrozen, Takeda, Theravance and UCB. Wehkamp reports no relevant financial disclosures.…
In this episode of Meeting Mic, we bring you Healio’s top headlines from DDW 2023. Jessica R. Allegretti, MD, MPH, reviews the results of a Tremfya study presented at the meeting. :09 Ken Blount, PhD, discusses restoration of gut microbiota and clonal engraftment after treatment with Rebyota. 4:07 Evan S. Dellon, MD, MPH, explains the improvements of mepolizumab seen in patients with eosinophilic esophagitis. 10:50 Jessica R. Allegretti also discusses the treatment with Rebyota in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection. 15:16 Shrujal Baxi, MD, MPH, describes the use of artificial intelligence for polyp detection for colorectal cancer. 19:26 Paul Limburg, MD, MPH, AGAF, reviews the revised guidelines and the push for non-invasive screening methods for colorectal cancer. 24:07 Read the full coverage here: https://www.healio.com/news/gastroenterology/20230509/video-patients-with-uc-achieve-symptomatic-remission-as-early-as-week-4-with-tremfya https://www.healio.com/news/gastroenterology/20230509/video-distinctive-shift-in-gut-microbiota-after-rebyota-treatment-for-c-difficile https://www.healio.com/news/gastroenterology/20230510/video-mepolizumab-for-eoe-does-not-yield-prominent-symptom-improvement-after-6-months https://www.healio.com/news/gastroenterology/20230509/video-no-change-in-concomitant-medications-after-rebyota-for-recurrent-c-difficile-ibd…
In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition. Mikkael A. Sekeres, MD, MS, chief of the division of hematology and professor of medicine at Sylvester Comprehensive Cancer Center and University of Miami Health System and chair of the ASH committee on communications, discusses some key take-home points from the Long COVID presentation. :00 Shakira J. Grant, MBBS, discusses multilevel interventions required to increase the rate at which Black individuals participate in hematology research studies. 3:44 Arushi Khurana, MBBS, reviews criteria used to disqualify patients from participating in front-line clinical trials, the acceptable ranges of which often prohibited Black and Hispanic patients from enrollment. 6:35 Tatyana Feldman, MD, discusses how the addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma. 9:32 Warren B. Fingrut, MD, reviews how hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry. 12:02 Read the full coverage here: Restrictive diet an 'unnecessary burden' for patients undergoing HSCT Multilevel interventions needed to reduce racial disparities in clinical trial enrollment Eligibility criteria more likely to exclude minorities from lymphoma clinical trials Combination ‘promising’ for advanced classical Hodgkin lymphoma Non-European HSCT recipients undergo more complex procedures with fewer resources Disclosures: Feldman reports consulting/advisory roles with, speakers bureau roles with or other financial relationships with AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genmab, Genomic Testing Cooperative, Janssen, Karyopharm Therapeutics, Kite Pharma, MorphoSys, Pharmacyclics, Secura Bio, Seagen and Takeda. Please see the abstract for all other researchers’ relevant financial disclosures. Fingrut reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures. Grant reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures. Khurana reports no relevant financial disclosures.…
In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio’s top headlines from the meeting. Virginia G. Kaklamani, MD, DSc, professor of medicine in the division of hematology/oncology at UT Health San Antonio and leader of the breast cancer program at UT Health San Antonio MD Anderson Cancer Center, reviews an abstract presentation on the impact of cyclin-dependent kinase 4/6 inhibitor therapy in patients with advanced breast cancer :00 Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School, discusses a study on trastuzumab-deruxtecan and its response rate in patients with early breast cancer 5:00 Sara A. Hurvitz, MD, FACP, medical oncologist at UCLA Health, Santa Monica Medical Center, associate professor at David Geffen School of Medicine at UCLA, medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, and director of the breast cancer clinical trials program at UCLA, examines trastuzumab-deruxtecan’s effect on patients with breast cancer who were previously treated with trastuzumab and a taxane. 10:00 Read the full coverage here: Longer CDK 4/6 inhibitor therapy enhances elacestrant benefit in metastatic breast cancer Elacestrant extends PFS among certain women with metastatic breast cancer Trastuzumab deruxtecan ‘new gold standard’ in second line for breast cancer subset Ribociclib regimen may be superior to chemotherapy in advanced breast cancer Breast cancer specialist receives lecture award Genomic assay may predict ovarian function suppression benefit in breast cancer subset Disclosures: Bardia reports research funding from or consultant/advisory roles with AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Immunomedics/Gilead Sciences, Merck, Novartis, Pfizer, Radius Health and Sanofi. Hurvitz reports honoraria from Daichi Sankyo and research funding to her institution from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX Therapeutics, Daiichi Sankyo, Dantari, Dignitana, Eli Lilly, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, MacroGenics, Novartis, OBI Pharma, Orinoco Pharmaceuticals, Pfizer, Phoenix Molecular Designs, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Samumed, Sanofi, Seagen and Zymeworks. She also reports her spouse is a shareholder/stockholder in Ideal Implant. Kaklamani reports honoraria from, consultant/advisory roles with, speakers bureau roles with or other relationships with AstraZeneca, Daiichi Sankyo, Genentech, Genomic Health, Gilead Sciences, Novartis, Pfizer and Puma Biotechnology. Please see the abstract for all other researchers’ relevant financial disclosures.…
In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio’s top headlines from the meeting. Alfred Kim, MD, discusses some key take-home points from the Long COVID presentation :18 Giovanni Adami, MD, reviews the impact of tofacitinib on fracture risk in patients with rheumatoid arthritis and the effect of glucocorticoids on bone density. 3:39 Leonard Calabrese, DO, gives a long-view of the meeting and the sessions he attended. 6:06 Paul Emery, MD, discusses results of a phase 2 study of peresolimab for adults with rheumatoid arthritis. 9:32 Read the full coverage here: https://www.healio.com/news/rheumatology/ 20221112/understanding- of-long-covid-shifting-at- breakneck-speed https://www.healio.com/news/rheumatology/ 20221122/bonesafe-glucocorticoid- dose-hard-to-find-in- rheumatic-musculoskeletal- diseases https://www.healio.com/news/rheumatology/ 20221121/pd1-agonist-generates-a-bit-of-excitement- in- rheumatoid- arthritis ACR: Varicella vaccine strongly recommended in all immunosuppressed adults ‘Anatomy inventory’ fosters more inclusive care for transgender, non-binary patients 'Strange times’: Prescribing methotrexate legally ‘low risk’ Post-Roe Disclosures: Adami reports consultant roles with Amgen, BMS, Eli Lilly, Fresenius Kabi, Galapagos, Theramex and UCB. Calabrese reports consultant roles with AstraZeneca and GSK. Emery reports relationships with AbbVie/Abbott, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galapagos, Gilead, Novartis, Pfizer, Roche and Samsung. Kim reports no relevant financial disclosures.…
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.